Report cover image

Anti-Inflammatory Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Dec 01, 2024
Length 155 Pages
SKU # FOB19410767

Description

Anti-Inflammatory Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Anti-Inflammatory Drugs Market

The anti-Inflammatory drugs market size was valued at USD 93.88 billion in 2019, and the market is now projected to be USD 299.95 billion by 2032, exhibiting a CAGR of 9.4% during the forecast period of 2020-2032.

SARS-COV 2 has caused severe irritation to affect a patient which has encouraged drug production. The consequence of these problems led to increased R&D activities for the treatment. Various anti-incendiary medicines were used to manage fever, pain and irritation associated with the pandemic during the initial phase of the pandemic. On the other hand, concerns were raised regarding the potential unhelpful effects of antipyretic analgesics. This has raised concern for utilization of these medicines. These concerns stem from the fact that NSAIDs might potentially get worse the immune response and augment the threat of complications. Hence, the COVID-19 pandemic has created both opportunities and barriers for the anti-Inflammatory drugs market growth.

The anti-Inflammatory drugs market share globally has increased because of the growing probability of pipeline applicants. Increasing research expenditures for the improvement of biologics for the treatment of autoimmune inflammatory diseases has resulted in latent pipeline drugs. The companies are focusing on targeting broad provocative diseases with anti-tumor necrosis factor, interleukins, and others. The advantages of such drugs of monoclonal antibodies have changed the attention of pharmaceutical giants towards this area. In addition, the rising uptake of corticoid for the cure of asthma and chronic obstructive pulmonary disease (COPD) and the budding incidence of atopic dermatitis are predictable to put in force to the market growth.

The trend is growing focus on developing biosimilars with major pharmaceutical companies is fuelling the market growth. A lot of manufactures have shifted their attention to the development of biosimilars owing to the greater than ever demand and easy approval process when compared to a novel drug. Biosimilars of infliximab, adalimumab, and etanercept are endeavoring at attracting high revenue in the market with their reference biologics namely Humira, Ramicade, and Enbrel. This has become an important market drift.

Comprehensive Analysis of Anti-Inflammatory Drugs Market

The anti-Inflammatory drugs market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional evaluation considering the dominant supply and demand forces that impact the healthcare industry. These segmentations are methodically divided by drug class, application, route of administration, and distribution channel. The drug classes are NSAIDs, anti-inflammatory biologics, and corticosteroids. The applications comprise autoimmune-inflammatory diseases and respiratory. The route of administration involves oral, injection, inhalation, and topical; whereas the distribution channels include hospital pharmacy and retail pharmacy.

The North American region is conducive to the global anti-Inflammatory drugs market, leading to a recall of USD 41.39 billion owing to increasing demand for drugs, government-support, and significant research investments are propelling the market expansion.

The top players in the market play a vital role in the healthcare industry assuring industrial prospectus growth and setting market values. These players are Pfizer Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline plc., Eli Lilly and Company, Biogen, Amgen Inc., Novartis AG, and AbbVie Inc., these market players present a level-playing competitive landscape.

In December 2019, Union Chimique Belge did Phase 3 active-controlled BE SURE study in which they had declared positive results. It has compared the investigational IL-17A and IL-17F inhibitor bimekizumab to the TNF inhibitor adalimumab in the treatment of adults with moderate-to-severe plaque psoriasis.

Segmentation Table

Global Anti-Inflammatory Drugs Market Scope

ATTRIBUTE DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD billion)

SegmentationBy Drug Class

Anti-inflammatory Biologics

Non-steroidal Anti-inflammatory Drugs (NSAIDs)

Corticosteroids

By Application

Autoimmune Inflammatory Diseases

Rheumatoid Arthritis

Psoriasis

Others

Respiratory Diseases

Others

By Route of Administration

Oral

Injection

Topical

Inhalation

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

By Geography

North America (the U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)

Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)

Latin America (Brazil, Mexico, and the Rest of Latin America)

Middle East& Africa (South Africa, GCC and the Rest of Middle East & Africa)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

155 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Prevalence of Major Diseases – For Key Countries
4.2. Pipeline Analysis
4.3. Patent Snapshot
4.4. New Product Launches
4.5. Key Industry Developments - Mergers, Acquisitions and Partnerships
5. Global Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1. Anti-inflammatory Biologics
5.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
5.2.3. Corticosteroids
5.3. Market Analysis, Insights and Forecast – By Application
5.3.1. Autoimmune Inflammatory Diseases
5.3.1.1. Rheumatoid Arthritis
5.3.1.2. Psoriasis
5.3.1.3. Others
5.3.2. Respiratory Diseases
5.3.3. Others
5.4. Market Analysis, Insights and Forecast – By Route of Administration
5.4.1. Oral
5.4.2. Injection
5.4.3. Inhalation
5.4.4. Topical
5.5. Market Analysis, Insights and Forecast – By Distribution Channel
5.5.1. Hospital Pharmacy
5.5.2. Retail Pharmacy
5.5.3. Online Pharmacy
5.6. Market Analysis, Insights and Forecast – By Region
5.6.1. North America
5.6.2. Europe
5.6.3. Asia Pacific
5.6.4. Latin America
5.6.5. Middle East & Africa
6. North America Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Drug Class
6.2.1. Anti-inflammatory Biologics
6.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
6.2.3. Corticosteroids
6.3. Market Analysis, Insights and Forecast – By Application
6.3.1. Autoimmune Inflammatory Diseases
6.3.1.1. Rheumatoid Arthritis
6.3.1.2. Psoriasis
6.3.1.3. Others
6.3.2. Respiratory Diseases
6.3.3. Others
6.4. Market Analysis, Insights and Forecast – By Route of Administration
6.4.1. Oral
6.4.2. Injection
6.4.3. Inhalation
6.4.4. Topical
6.5. Market Analysis, Insights and Forecast – By Distribution Channel
6.5.1. Hospital Pharmacy
6.5.2. Retail Pharmacy
6.5.3. Online Pharmacy
6.6. Market Analysis, Insights and Forecast – By Country
6.6.1. U.S.
6.6.2. Canada
7. Europe Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast – By Drug Class
7.2.1. Anti-inflammatory Biologics
7.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
7.2.3. Corticosteroids
7.3. Market Analysis, Insights and Forecast – By Application
7.3.1. Autoimmune Inflammatory Diseases
7.3.1.1. Rheumatoid Arthritis
7.3.1.2. Psoriasis
7.3.1.3. Others
7.3.2. Respiratory Diseases
7.3.3. Others
7.4. Market Analysis, Insights and Forecast – By Route of Administration
7.4.1. Oral
7.4.2. Injection
7.4.3. Inhalation
7.4.4. Topical
7.5. Market Analysis, Insights and Forecast – By Distribution Channel
7.5.1. Hospital Pharmacy
7.5.2. Retail Pharmacy
7.5.3. Online Pharmacy
7.6. Market Analysis, Insights and Forecast – By Countries/ Sub-region
7.6.1. U.K.
7.6.2. Germany
7.6.3. France
7.6.4. Spain
7.6.5. Italy
7.6.6. Scandinavia
7.6.7. Rest of Europe
8. Asia Pacific Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast – By Drug Class
8.2.1. Anti-inflammatory Biologics
8.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
8.2.3. Corticosteroids
8.3. Market Analysis, Insights and Forecast – By Application
8.3.1. Autoimmune Inflammatory Diseases
8.3.1.1. Rheumatoid Arthritis
8.3.1.2. Psoriasis
8.3.1.3. Others
8.3.2. Respiratory Diseases
8.3.3. Others
8.4. Market Analysis, Insights and Forecast – By Route of Administration
8.4.1. Oral
8.4.2. Injection
8.4.3. Inhalation
8.4.4. Topical
8.5. Market Analysis, Insights and Forecast – By Distribution Channel
8.5.1. Hospital Pharmacy
8.5.2. Retail Pharmacy
8.5.3. Online Pharmacy
8.6. Market Analysis, Insights and Forecast – By Countries/ Sub-region
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. Australia
8.6.5. Southeast Asia
8.6.6. Rest of Asia Pacific
9. Latin America Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis, Insights and Forecast – By Drug Class
9.2.1. Anti-inflammatory Biologics
9.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
9.2.3. Corticosteroids
9.3. Market Analysis, Insights and Forecast – By Application
9.3.1. Autoimmune Inflammatory Diseases
9.3.1.1. Rheumatoid Arthritis
9.3.1.2. Psoriasis
9.3.1.3. Others
9.3.2. Respiratory Diseases
9.3.3. Others
9.4. Market Analysis, Insights and Forecast – By Route of Administration
9.4.1. Oral
9.4.2. Injection
9.4.3. Inhalation
9.4.4. Topical
9.5. Market Analysis, Insights and Forecast – By Distribution Channel
9.5.1. Hospital Pharmacy
9.5.2. Retail Pharmacy
9.5.3. Online Pharmacy
9.6. Market Analysis, Insights and Forecast – By Countries/ Sub regions
9.6.1. Brazil
9.6.2. Mexico
9.6.3. Rest of Latin America
10. Middle East & Africa Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis, Insights and Forecast – By Drug Class
10.2.1. Anti-inflammatory Biologics
10.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
10.2.3. Corticosteroids
10.3. Market Analysis, Insights and Forecast – By Application
10.3.1. Autoimmune Inflammatory Diseases
10.3.1.1. Rheumatoid Arthritis
10.3.1.2. Psoriasis
10.3.1.3. Others
10.3.2. Respiratory Diseases
10.3.3. Others
10.4. Market Analysis, Insights and Forecast – By Route of Administration
10.4.1. Oral
10.4.2. Injection
10.4.3. Inhalation
10.4.4. Topical
10.5. Market Analysis, Insights and Forecast – By Distribution Channel
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Analysis, Insights and Forecast – By Countries/ Sub region
10.6.1. South Africa
10.6.2. GCC
10.6.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2019)
11.3. Company Profiles (Overview, Product & Services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.3.1. AbbVie Inc.
11.3.1.1. Overview,
11.3.1.2. Product & Services,
11.3.1.3. SWOT analysis,
11.3.1.4. Recent developments,
11.3.1.5. strategies,
11.3.1.6. financials (based on availability)
11.3.2. Johnson & Johnson Services, Inc.
11.3.2.1. Overview,
11.3.2.2. Product & Services,
11.3.2.3. SWOT analysis,
11.3.2.4. Recent developments,
11.3.2.5. strategies,
11.3.2.6. financials (based on availability)
11.3.3. Bristol-Myers Squibb Company
11.3.3.1. Overview,
11.3.3.2. Product & Services,
11.3.3.3. SWOT analysis,
11.3.3.4. Recent developments,
11.3.3.5. strategies,
11.3.3.6. financials (based on availability)
11.3.4. Merck & Co., Inc.
11.3.4.1. Overview,
11.3.4.2. Product & Services,
11.3.4.3. SWOT analysis,
11.3.4.4. Recent developments,
11.3.4.5. strategies,
11.3.4.6. financials (based on availability)
11.3.5. Pfizer Inc.
11.3.5.1. Overview,
11.3.5.2. Product & Services,
11.3.5.3. SWOT analysis,
11.3.5.4. Recent developments,
11.3.5.5. strategies,
11.3.5.6. financials (based on availability)
11.3.6. Novartis AG
11.3.6.1. Overview,
11.3.6.2. Product & Services,
11.3.6.3. SWOT analysis,
11.3.6.4. Recent developments,
11.3.6.5. strategies,
11.3.6.6. financials (based on availability)
11.3.7. GlaxoSmithKline plc.
11.3.7.1. Overview,
11.3.7.2. Product & Services,
11.3.7.3. SWOT analysis,
11.3.7.4. Recent developments,
11.3.7.5. strategies,
11.3.7.6. financials (based on availability)
11.3.8. Eli Lilly and Company
11.3.8.1. Overview,
11.3.8.2. Product & Services,
11.3.8.3. SWOT analysis,
11.3.8.4. Recent developments,
11.3.8.5. strategies,
11.3.8.6. financials (based on availability)
11.3.9. Amgen Inc.
11.3.9.1. Overview,
11.3.9.2. Product & Services,
11.3.9.3. SWOT analysis,
11.3.9.4. Recent developments,
11.3.9.5. strategies,
11.3.9.6. financials (based on availability)
11.3.10. Biogen
11.3.10.1. Overview,
11.3.10.2. Product & Services,
11.3.10.3. SWOT analysis,
11.3.10.4. Recent developments,
11.3.10.5. strategies,
11.3.10.6. financials (based on availability)
11.3.11. Other Prominent Players
11.3.11.1. Overview,
11.3.11.2. Product & Services,
11.3.11.3. SWOT analysis,
11.3.11.4. Recent developments,
11.3.11.5. strategies,
11.3.11.6. financials (based on availability)
12. Strategic Recommendations

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us